Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioblastoma: early-phase trial registry
78 of 200 indexed Glioblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #49 of 28,707 conditions by registered trial count.
200 US clinical trials · 78 currently recruiting · #49 of 28,707 conditions by registered trial count
Glioblastoma: 200 US clinical trials tracked, 78 recruiting.
Glioblastoma is the subject of 200 registered US clinical trials on ClinicalTrials.gov, 78 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 148 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 10 of these trials.
Enrollment posture brief
Registry condition glioblastoma
OPEN 78 | RECR 39% | LATE 15 | EARLY 148 | RANK #49 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Chronic Myeloid Leukemia (39% recruiting · 36 trials)
Glioblastoma lists 78 open slots (39% of 200 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioblastoma recruits in line with its size-band peers.
78 of 200 indexed trials (39%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Glioblastoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 10 of 200 trials (5%). 112 distinct sponsors appear on at least one study for this condition label.
-
Most Glioblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 200 trials that report a genuine target (sentinel values excluded). 153 of those (76.5%) plan for fewer than 100 participants.
-
Glioblastoma research is mostly interventional.
186 interventional and 14 observational studies make up this index (93% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
200 total, page 2 of 4
Evaluation of the CONVIVO System
Dartmouth-Hitchcock Medical Center
NCT05139277
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
NCT06058988
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
SignPath Pharma
NCT05768919
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
NCT04555577
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Ugonma Chukwueke
NCT06552260
Glioblastoma Remote Monitoring and Care - Research Protocol
Case Comprehensive Cancer Center
NCT06129760
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
NCT04863950
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
NCT05698524
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Emory University
NCT04590664
CARv3-TEAM-E T Cells in Glioblastoma
Marcela V. Maus, M.D.,Ph.D.
NCT05660369
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
Medical College of Wisconsin
NCT03194971
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
Columbia University
NCT06108206
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
University of California, Davis
NCT07145112
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Sabine Mueller, MD, PhD
NCT04323046
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
Hideho Okada, MD, PhD
NCT06186401
Methimazole in Patients With Progressive Glioblastoma
Case Comprehensive Cancer Center
NCT05607407
CUE-102 in Recurrent Glioblastoma
David Reardon, MD
NCT06917885
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Henry Ford Health System
NCT05686798
PH Sensitive MRI Based Resections of Glioblastoma
University of California, Los Angeles
NCT06176066
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
NCT06333899
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
Jonsson Comprehensive Cancer Center
NCT07461948
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
Abramson Cancer Center at Penn Medicine
NCT06613841
Implantable Microdevice In Primary Brain Tumors
Oliver Jonas
NCT04135807
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
NCT06831526
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Nader Sanai
NCT05773326
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT05979064
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Case Comprehensive Cancer Center
NCT05565118
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
University of Pennsylvania
NCT06973096
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NRG Oncology
NCT02179086
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
CarThera
NCT05902169
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
NCT02152982
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Universitätsmedizin Mannheim
NCT02685605
Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
Memorial Sloan Kettering Cancer Center
NCT02375841
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
NCT05095376
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
Mayo Clinic
NCT05781321
Pediatric Long-Term Follow-up and Rollover Study
Novartis Pharmaceuticals
NCT03975829
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Nerviano Medical Sciences
NCT04910022
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Theodore S. Johnson
NCT04049669
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT04478279
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03251027
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Nader Sanai
NCT05182905
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Imvax
NCT04485949
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
David Peereboom
NCT03452579
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
National Cancer Institute (NCI)
NCT03212274
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
NCT01903330
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
University of California, San Francisco
NCT03749187
Mind-Body Intervention in Glioma Couples
M.D. Anderson Cancer Center
NCT03244995
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
University of Pennsylvania
NCT05168423
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
NCT02455557
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 61 |
| Phase 3 | 13 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioblastoma page
200 registered trials, 78 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 78 Glioblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Glioblastoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioblastoma condition card totals 200 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.